Llwytho...
First Allogeneic CAR T‐Cell Therapy Impresses in Relapsed/Refractory Lymphoma
In the phase I ALPHA trial, the first allogeneic “off‐the‐shelf” CAR T‐cell therapy regimen showed clinical benefits in patients with relapsed/refractory large B‐cell or follicular lymphoma.
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Oncologist |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley & Sons, Inc.
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7330918/ https://ncbi.nlm.nih.gov/pubmed/32588932 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0570 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|